What is "pardoprunox"

n. An antiparkinsonian drug.

Pardoprunox ( INN) (code name SLV-308) is an antiparkinsonian drug currently that was under development by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.1 It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.

Pardoprunox acts as a D (pK = 8.1) and D receptor (pK = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT receptor (pK = 8.5) full agonist (IA = 100%). It also binds to D (pK = 7.8), α-adrenergic (pK = 7.8), α-adrenergic (pK = 7.4), and 5-HT receptors (pK = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.